GRN 1201

Drug Profile

GRN 1201

Alternative Names: GRN-1201

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GreenPeptide
  • Developer BrightPath Biotherapeutics
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Malignant melanoma

Most Recent Events

  • 01 Jun 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT03417882)
  • 01 Jun 2018 Phase-II clinical trials in Non-small cell lung cancer (Newly diagnosed, Metastatic disease, Combination therapy, First-line therapy) in USA (Intradermal) (NCT03417882)
  • 01 Mar 2018 BrightPath Biotherapeutics completes a phase I trial in Malignant melanoma in USA (Intradermal) (NCT02696356)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top